Save on Skyrizi with Coupons, Discounts & Savings Programs

Skyrizi is the brand name for risankizumab-rzaa and is available as an injection for subctuaneous or IV use.

Skyrizi is available as follows:

• Subcutaneous injection
• 150 mg/mL in each single-dose prefilled pen
• 90 mg/mL in each single-dose prefilled syringe
• 150 mg/mL in each single-dose prefilled syringe
• 180 mg/1.2 mL (150 mg/mL) in each single-dose prefilled cartridge
• 360 mg/2.4 mL (150 mg/mL) in each single-dose prefilled cartridge
• Intravenous infusion 600 mg/10 mL (60 mg/mL) in each single-dose vial

• Skyrizi is a monoclonal antibody that is used to treat:
• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Moderate-to-severe Crohn’s disease

Skyrizi is a monoclonal antibody that works as an interleukin antagonist. It attaches to certain proteins in your immune system called interleukin-23 (IL-23) that play a role in causing inflammation. This stops the proteins from getting turned on, which helps lower inflammation.

• Skyrizi is dosed as follows:
• Plaque psoriasis and psoriatic arthritis: The typical starting dose is 150 mg injected under the skin once every month for the first 2 doses. Then, it’s given once every 3 months.
• Crohn’s disease: The typical starting dose is 600 mg infused through the veins (intravenous or IV) once every month for the first 3 doses. Then one month later, the dose changes to 180 mg or 360 mg injected under the skin that’s given once every 2 months.

Skyrizi is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. Skyrizi is contraindicated in patients with a history of serious
hypersensitivity reaction to risankizumab-rzaa or any of the excipients.

• Common side effects of Skyrizi:
• Upper respiratory infections
• Joint pain
• Headache
• Tiredness
• Injection site reaction (e.g., bruising, redness, pain, swelling, itching, warmth, bleeding, irritation)

Serious side effects are rare with Skyrizi. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic reactions: difficulty breathing; hives; swelling of your face, lips, tongue, or throat
  Infection: fever; cough; difficulty breathing; diarrhea; weakness; sweating; chills; scaly, itchy, or burning skin

• There are no major drug interactions listed for Skyrizi. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

AbbVie Inc.

Although there are no data on risankizumab-rzaa, monoclonal antibodies can be actively transported across the placenta, and Skyrizi may cause immunosuppression in the in utero-exposed infant. Skyrizi should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while treated with Skyrizi. Patients should be encouraged to enroll by calling 1-877-302-2161 or
visiting  glow pregnancy registry 

• Risankizumab-RZAA